ArticleHealth science reports2022
RSV-associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomes.
Article in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries.Infectious diseases and therapy · 2026Pooled it
- Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System.Open forum infectious diseases · 2026Article
- Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.Lancet regional health. Americas · 2026Article
- Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.Open forum infectious diseases · 2026Article
- Exploring the Link Between RSV Infection and Antibiotic Prescriptions in Older Adults: A Systematic Review.Antibiotics (Basel, Switzerland) · 2026Review
- Estimating the burden of RSV- and influenza-associated ED visits, hospitalizations, ICU admissions, and deaths across age and socioeconomic groups in New York State, 2005-2019.BMC infectious diseases · 2026Article
- Article
- Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries.Frontiers in public health · 2026Article
- Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status.Infectious diseases and therapy · 2026Article
- Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications.The Journal of infectious diseases · 2025Observational
- Long-Term Trends in Respiratory Syncytial Virus A Infections (2007-2024) in Korea.Diseases (Basel, Switzerland) · 2025Article
- Analyzing Differences in Viral Dynamics Between Vaccinated and Unvaccinated RSV Patients.Epidemiologia (Basel, Switzerland) · 2025Article
- RSV: an update on prevention and management.Australian prescriber · 2025Review
- Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults.JAMA network open · 2024Article
- Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection.BMC pulmonary medicine · 2024Observational
- Severe respiratory syncytial virus disease.Journal of intensive medicine · 2024Review
- Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- IL-1α is required for T cell-driven weight loss after respiratory viral infection.Mucosal immunology · 2024Article
- Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults.Infection & chemotherapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The burden of respiratory syncytial virus (RSV) infection in adults is of growing concern. This study was designed to quantify disease burden, treatment approaches, and outcomes associated with RSV infections in adult subpopulations, from prehospitalization to hospital discharge. Methods: A retrospective chart analysis was conducted to collect patient-case data from hospitalized US adults (aged >18 years) with RSV infection during two RSV seasons. Patients were categorized into risk groups: comorbid lung disease, immunocompromised, older adults (aged ≥65 years), and other adults (aged <65 years). Physicians reported diagnosis, treatment choices including respiratory supportive therapy (oxygen and fluid supplementation), and outcome variables using a standardized online case form. Results: The majority (277/379; 73%) of patients presented to the emergency room, with a mean age of 60 years. Once hospitalized, the median length of stay was 6.0 days (3.0-9.0), with disease severity having the greatest impact on duration of stay. No significant between-group differences in rates of patients requiring management in intensive care units were found (comorbid lung disease, 28%; immunocompromised, 36%; older adults, 26%; and other adults, 23%). Overall, respiratory supportive therapy was the most commonly used form of treatment. Antibiotics were administered in over half of all risk groups (comorbid lung disease, 61%; immunocompromised, 59%; older adults, 59%; and other adults, 51%). Patients usually required follow-up visits following discharge, with 10%-16% requiring skilled nursing care and approximately 25% requiring assistance from a social worker. Conclusion: RSV in adult subpopulations, irrespective of age, is a significant burden to healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.